Sera of patients with breast cancer, of healthy women from the United States, East India, East Africa, and China, and of healthy women of American and Parsi families in which breast cancer occurred in several family members were assayed for levels of antibody reactive with the murine mammary tumor virus (MuMTV) by an enzyme-linked immunosorbent assay. Increased levels of antibody to MuMTV (absorbance -0.4) were found in sera of 18.6% ofAmerican patients with breast cancer and of 2.8% of healthy American women and in 38% of patients from India and 61.9% from East Africa (healthy, 26.9%). In contrast, antibody reactive with MuMTV was found in <5 of women with breast cancer from mainland China (healthy Chinese, 5.0%). Differences in serum MuMTV antibody levels between breast cancer patients in the four groups were found to be significant (P < 0.0001). Studies of two families from the United States and of one Parsi family from India with genetic propensity to breast cancer showed that high levels ofantibody to MuMTV were found in 33%, 71%, and 23% of healthy family members, respectively. The antibody to MuMTV was readily absorbed with purified MuMTV and gp52. In contrast, fetal calf serum, murine type C retroviruses, or erythrocytes from various species failed to absorb the antibody. A relationship between human breast cancer and murine mammary tumor virus (MuMTV) has been suggested from several observations. RNA partially homologous to the MuMTV genome was identified in human breast cancer tissue (1). Lymphocytes from individuals with breast cancer were shown to proliferate after stimulation by MuMTV (2, 3). Sera from breast cancer patients decreased the infectivitity of MuMTV in mice (4), suggesting the presence of antibodies against the virus. More recently, using immunoperoxidase staining, Mesa-Tejada et al. (5) found that antigen reacting with antibody to the envelope glycoprotein of MuMTV (gp52) could be detected in breast cancer tissue. Ohno et al. (6) have now demonstrated that this crossreactivity is directed to the protein moiety ofgp52 and not the carbohydrate.
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In prior studies using a virolytic assay with complement and antibody, we found that antibodies reactive with MuMTV are present in sera of approximately 20% of American women with breast cancer (7). Sera of age-matched healthy women and of patients with other cancers had such antibodies in lower frequency. We developed a method to detect these antibodies directly by using MuMTV and an enzyme-linked immunosorbent assay (ELISA) (8) . With this method also we found that sera of approximately 25% of American women with breast cancer had antibodies to MuMTV. Approximately 10% ofwomen with benign cystic disease of the breast also had such antibodies in their sera (8) . Reactivity was inhibited by the membrane proteins of MuMTV (gp52 and gp34) but not by the core antigen (p28) (9) .
We now report results on the specificity of the human antibody for MuMTV Patient Sera. Blood samples (5-10 ml) without anticoagulants were drawn under sterile conditions and the sera were prepared by established procedures (10), divided into 100-,ul aliquots, and stored at -70°C. Sera from abroad were shipped to the United States in dry ice.
Viruses and Purified Preparation of the Virus. MuMTV was purified from cultures of MuMT-73 murine mammary epithelial cell line as described (11) . gp52, the purified membrane antigen, was prepared according to published procedures (12) . AKR and Rauscher murine leukemia viruses were purified as described for the MuMTV. Determination ofAntibody to MuMTV by ELISA. Sera were assayed by ELISA for presence of antibody reactive with MuMTV by described methods (8) . Briefly, sera were diluted 1:30 in phosphate-buffered saline containing 0.05% Tween 20 (PJNaCl/Tween) and incubated in microtiter plate wells containing 0.5 ,ug of fixed MuMTV. After 2 hr, the wells were washed with PJNaCI/Tween, and alkaline phosphatase-conjugated swine anti-human IgG (Orion Diagnostics, Helsinki, Finland) was added to the wells. After 120 min, the wells were again washed with PJNaCl/Tween and the alkaline phosphatase substrate p-nitrophenyl phosphate was added. After 30-60 min, the reaction was stopped with 3 M NaOH and the absorbance of the yellow color was determined at 400 nm in a spectrophotometer. The observed absorbance is proportional to viral protein over the range 0.1-10 ,ug, and rabbit antibody to MuMTV is readily detectable at dilutions up to 1:3000 (8 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
30 min) test serum with positive antibody titer determined by the ELISA. The reaction mixture was incubated at 37C for 60 min. The mixture was centrifuged at 10,000 X g for 5 min and halfofthe supernatant was removed. This process was repeated three times and the supernatants were analyzed by the ELISA. The above procedure was repeated with the AKR and Rauscher murine leukemia and purified gp52.
Absorption with erythrocytes from human, sheep, bovine, equine, and guinea pig sera was carried out as above with equal volumes ofwashed (three times) erythrocytes ofvarious species (1 X 108/ml) and serum.
Blocking Studies. High-titered antisera were incubated with MuMTV or AKR murine leukemia virus (0. 5 mg/ml) or various carbohydrates (1 mg/ml) in a final volume of 150 /.l and incubated at 370C for 60 min and at 40C for 18 hr. After centrifugation, the supernatants were assayed by the ELISA for binding to MuMTV.
Analysis of Results. The results are expressed (a) as the percentage of patients in each group with increased levels of antibody to MuMTV (background absorbance ofsera of50 healthy women .0.4) at 1:30 dilution and (b) as the mean of individual values of antibody to MuMTV. The two-sample t test was used to detect differences between mean MuMTV antibody levels ofbreast cancer and healthy groups ofeach nationality. One-way analysis ofvariance was used to detect differences among mean MuMTV antibody levels ofhealthy groups ofthree nationalities, among breast cancer groups of four nationalities, and among breast cancer groups of three East Indian communities in the Bombay area. Multiple comparisons by Fisher's least significant difference procedure were made when appropriate. Preincubation ofthe serum with MuMTV prevented binding of the antibody to MuMTV coated on microtiter plates (Fig. 2) . In contrast, preincubation with glycogen or another murine retrovirus, the type C AKR leukemia virus, did not prevent the binding of the antibody to MuMTV. Similar results were obtained when D-galactose, N-acetyl-D-galactosamine, L-fucose, or D-mannose were substituted for glycogen (data not shown). Furthermore, no significant changes in background binding were observed after absorption ofnormal serum with MuMTV, gp52, or various erythrocytes.
RESULTS

Specificity of Antibody in
Geographical Study of Antibody in Sera of Patients with Breast Cancer. Fig. 3 (Fig. 4) . The mean levels of antibody reactive to MuMTV in sera ofhealthy Chinese, American, East African, and East Indian women were also compared. The four groups were found to be significantly different (F, with 3 and 104 degrees of freedom, = 11.9; P < 0.0001). Specifically, the East Indian group had significantly higher mean levels of MuMTV antibody than the other three groups (mean, 0.5580). More father nor the mother of the propositus had breast cancer but both had significantly increased titers of antibody to MuMTV. Furthermore, in each ofthese the antibody was absorbable with MuMTV and gp52. All siblings (both male and female) of the propositus had increased titers ofantibody and in each case the antibody was absorbable with MuMTV and gp52.
In two other American families with high frequency ofbreast cancer (Fig. 7) , 33% of the members of family I and 71% of members of family II showed an increased titer of antibody to MuMTV. In family I the patients' sera did not show increased antibody levels whereas in family II, the patients' serum did.
Similar observations of frequently increased levels of antibody reactive to MuMTV were observed in family members of Parsi women with a high frequency of breast cancer. A representative Parsi family is illustrated in Fig. 8 represented on MuMTV, especially the envelope glycoprotein gp52. Various erythrocytes and other murine tumor viruses did not yield signficant absorption of the antibody under study. Futhermore, blocking of binding of antibody to MuMTV adherent to microtiter plates was not inhibited by glycogen or other sugars found in cell membranes but was completely inhibited by MuMTV.
These findings do not exclude the possibility that antibodies against heterophile antigens related to the virus may also occur in sera ofpatients with breast cancer. Antibodies in human sera to the glycoprotein of type C retroviruses appear to be directed to the sugar moiety (13) .
Several possibilities must be considered to explain our findings, of which one is that a virus or viruses related to MuMTV play a role in some patients with breast cancer. More likely is the possibility that gene sequences related to those determining MuMTV proteins are expressed in some patients with human breast cancer and that antibodies or autoantibodies to these antigenic determinants are sometimes made in humans with certain forms of breast cancer.
Perhaps the most striking of the findings in this report is that major differences in these antibody responses were found when sera of breast cancer patients from different parts of the world were investigated. Sera of women from Kenya with breast cancer had these antibodies in highest frequency and highest titers followed, in turn, by sera of breast cancer patients from East India, America, and China. The Chinese women with breast cancer had both the lowest titers and the lowest frequency of increased titers. The simplest interpretation ofthese data is that there exist multiple (at least two) separate forms ofbreast cancer and in one, antigens stimulate production of the anti-MuMTV antibodies. It is of interest in this regard that Levine et al. (14) recently demonstrated, by immunoperoxidase assay, an antigen that crossreacts immunohistochemically with gp52 of the MuMTV in large quantities in 70% of biopsy specimens (23/ 33) from Tunisian breast cancer patients compared with 47% ofAmerican breast cancer biopsy speciments. In contrast, even significantly less antigen was present in Japanese breast cancer biopsies (Sol Spiegelman, Columbia University, New York, personal communication). The parallel with our observations, and thus the complementarity of the two findings, is obvious.
That genetic factors or factors in the immediate environment play a role in the expression of the antigenic stimulation that leads to the antibody response under study is suggested by the reported observations that breast cancer patients who are members of different communities in the Bombay area of India express these antibodies in different frequencies. These findings require more penetrating analysis. OA 6 Immunology: Day et al. 1.5 i.762 The findings from our studies of American and East Asian families in which breast cancer occurs in high frequency are also challenging. They show that increased titers ofantibody against MuMTV can occur in healthy female family members and even in some males. The latter antibodies also were absorbable with the virus and gp52. These family studies must be pursued in greater depth but they suggest the possibility that members at risk for breast cancer in such families may be identifiable by immunological analyses prior to the development or full expression of the breast cancer.
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